CMS Lowers Bone Stim Reimbursement, Impacting OFIX Outlook

Research evidence excerpt

CMS Lowers Bone Stim Reimbursement, Impacting OFIX Outlook

unless noted otherwise. The equity research price target

for an issuer's stock represents the value that the analyst reasonably expects the stock to reach over a performance period of twelve months. Any price targets in

equity securities in this report should be considered in the context of all prior published TD Cowen equity research reports (including the disclosures in any such equity

report or on the Firm's disclosure website), which may or may not include equity research price targets, as well as developments relating to the issuer, its industry and

the financial markets. For equity research price target valuation methodology and risks associated with the achievement of any given equity research price target,

please see the analyst's equity research report publishing such targets.

Recipients of this analysis or research report are to contact the representative in their local jurisdiction with regards to any matters or questions arising from, or in

connection with, the analysis or research report.

Australia

If you receive this document and you are domiciled in Australia, please note that it is intended to be issued for general information purposes only and distributed to a

person who is a wholesale client, as defined in the Corporations Act 2001 and Corporations Regulations 2001, by Toronto Dominion (South East Asia) Limited ("TDSEA").

TDSEA does not hold itself out to be providing financial advice in these circumstances. TD Securities is a trademark and represents certain investment dealing and

advisory activities of The Toronto-Dominion Bank and its subsidiaries, including TDSEA. The Toronto-Dominion Bank is not an authorized deposit-taking or financial

services institution in Australia.